Several studies over the past 3 decades document a higher prevalence of primary
aldosteronism (PA) among hypertensive patients than generally presumed. PA exists as a …

Background and objective The laboratory has a critical role to play in the screening and
diagnosis of primary aldosteronism. This review highlights some of the important analytical …

Methods We determined kidney function changes defined by cystatin C-based estimations of
glomerular filtration rate (CysC-GFR). Pretreatment proteinuria and intrarenal Doppler …

Primary aldosteronism (PA) is a pathological condition characterized by an excessive
aldosterone secretion; once thought to be rare, PA is now recognized as the most common …

Abstract Aldosterone synthase (CYP11B2) inhibition has emerged as a new option for the
treatment of hypertension, heart failure and renal disorders, in addition to mineralocorticoid …

It is now widely recognized that primary aldosteronism (PA) is much more common than
previously thought, accounting for up to 5–10% of hypertensives, and that aldosterone …

this context, a contribution of the adipose-tissue RAS, in addition to the classic RAS, is
discussed in the development of insulin resistance and hypertension. 26, 28 Studies …

Context Current threshold values for primary aldosteronism (PA) diagnostic testing are
based on measuring aldosterone (PAC) using immunoassays. Quantification of PAC by …

Regulation and action of the mineralocorticoid receptor (MR) have been the focus of
intensive research over the past 80 years. Genetic and physiological/biochemical analysis …

The source of aldosterone in 30–40% of patients with primary hyperaldosteronism (PA) is
unilateral aldosterone-producing adenoma (APA). The mechanisms causing elevated …